Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Birmingham, AlabamaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Denver, ColoradoAges 18 years+ - NCT03264352RecruitingPhase 4
Treatment for slightly high blood pressure in type 2 diabetes
This trial tests an intervention to help adults with type 2 diabetes who have “high-normal” blood pressure (not severely high). If you qualify, you may learn whether this approach improves blood pressure and related health outcomes over time.
Guangzhou, GuangdongAges 45–79 - NCT03581773RecruitingPhase 2
Folic acid to reduce mouth sores during kidney cancer treatment
This Phase 2 trial tests whether folic acid can lessen mucositis (painful mouth sores) caused by certain kidney cancer medicines. You would either take folic acid or an inactive pill, and the study looks for improvement in these side effects.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT03989323Recruiting
Register to track cancer immune therapy and side effects
This study sets up a real-world patient database to follow people starting cancer immunotherapy and record immune-related side effects. You may help doctors better understand who gets these side effects and how they change over time.
BronAges 18 years+ - NCT04419480Recruiting
Monitoring to help prevent complications after cardiogenic shock
This study tests a special monitoring approach (likely using an implanted device) to help prevent serious complications after you survive cardiogenic shock in the hospital. It may help the care team detect problems earlier so treatments can start sooner.
Falls Church, VirginiaAges 18 years+ - NCT04650607Recruiting
Phage therapy safety check in serious infection patients
This study checks the safety of using phage therapy (viruses that target certain bacteria) in adults being treated for serious infections. If you meet the safety rules, your care team may enroll you to help confirm phage treatment is safe.
LyonAges 18 years+ - NCT04807127Recruiting
Testing blood and lung fluid markers for lung side effects
This study tries to find early warning markers in lung fluid collected during a bronchoscopy (a camera test of the airways). The goal is to better spot and understand lung inflammation that can happen after immune checkpoint cancer treatments.
Leuven, Flemish BrabantAges 18–120 - NCT04824066Recruiting
Using wearables to spot complications early
This study checks whether common wearable devices can predict or detect problems after treatment or surgery. If you join, the researchers will compare what the wearable shows with what happens to you medically, to see if earlier warnings are possible.
Boston, MassachusettsAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
La Jolla, CaliforniaAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05125302RecruitingPhase 3
Ubrogepant for acute migraine relief in kids and teens
This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.
Huntsville, AlabamaAges 6–17 - NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05158894Recruiting
Pregnancy safety registry for migraine medicines Ubrelvy and Qulipta
This is an observational study (no treatment is assigned) that tracks side effects and pregnancy outcomes in people taking Ubrelvy or Qulipta for migraine during pregnancy. It may help doctors better understand how these medicines affect mothers and babies.
Durham, North CarolinaAges 18 years+ - NCT05407129Recruiting
Improve hospital safety by sharing your recent experience
This trial asks patients, families, caregivers, and hospital staff to report what happened during a recent hospital stay to help improve safety. Your feedback may help the hospital change processes that prevent problems for others.
Boston, MassachusettsAges Any age - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Tucson, ArizonaAges 18 years+ - NCT05527795Recruiting
Study features that predict benefit from extra immunotherapy in melanoma
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Pierre-BéniteAges 18 years+ - NCT05889182RecruitingPhase 3
Testing an oral medicine for moderate to severe hidradenitis
This Phase 3 study tests upadacitinib taken by mouth to reduce hidradenitis suppurativa (HS) symptoms and disease activity, and to track side effects. It is for people who have already tried anti-TNF treatments and still had inadequate response or couldn’t tolerate them.
Birmingham, AlabamaAges 12 years+ - NCT05908591Recruiting
Pregnancy sleep study on breathing, blood vessel function, and safety
This study looks at how sleep and breathing changes during pregnancy may affect blood vessel function and pregnancy safety. You may be asked about your sleep and possibly have health checks during the middle of pregnancy.
Edmonton, AlbertaAges 18 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 191 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.